Contributions
Abstract: EP1714
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Alemtuzumab is a disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS) that has shown efficacy in reducing the annualized relapse rate (ARR), the risk of sustained disability accumulation, and reduction in gadolinium-enhancing T1 lesions in cerebral magnetic resonance imaging (MRI) in patients with EDSS ≤ 5.
Objectives: To study effectiveness outcomes in patients with RRMS with EDSS scores of ≤ 5 or >5.
Methods: Retrospective observational study in patients with highly active RRMS treated with alemtuzumab from March 2015 to March 2017 at Virgen Macarena Hospital, Seville, Spain. Demographic/disease characteristics, ARR, changes in disability, and cerebral MRI findings were collected at enrolment.
Results: EDSS ≤ 5: 35 patients (23 females), mean age: 36.5 years, mean time to diagnosis 13.2 years. 16 patients have received two cycles of treatment. Mean EDSS score decreased from 3.4 to 2.6 (p< 0.05). 22 (62.9%) patients showed a reduction in EDSS, the remaining patients showed no changes in EDSS. ARR decreased from 1.8 to 0.1 (p< 0.05). Two patients (5.7%) experienced relapses after two cycles of treatment. T2 lesions on MRI showed no changes, but the mean number of gadolium enhancing lesions per patient decreased from 2.7 to 0.2 post-treatment (p< 0.05).
EDSS > 5: 27 patients (18 females), mean age: 42.7 years, mean time to diagnosis: 14.6 years. 14 patients have received two cycles of treatment. Mean EDSS score decreased from 6.6 to 5.9 (p< 0.05). 11 (40.7%) patients showed a reduction in EDSS. One patient showed an increase in EDSS of 0.5 points despite receiving the second cycle of treatment. The mean number of T2 lesions on MRI increased from 38.9 to 42.4, and the mean number of gadolinium enhancing lesions decreased from 1.2 to 0.25 (p< 0.05).
Conclusions: Our data show that alemtuzumab is an effective therapy for the treatment of RRMS irrespective of the EDSS score status, with significant improvement in EDSS score, ARR, and gadolinium-enhancing lesions in patients with EDSS score ≤ 5 or > 5. Larger studies are needed to confirm these results given the relatively small size of our patient population.
Disclosure:
Rocío López Ruiz received honoraria as consultant on scientific advisory boards from Biogen, Novartis and Genzyme.
Sara Eichau received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
JL Ruiz-Peña received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
G. Navarro received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
G. Izquierdo received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
Abstract: EP1714
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Alemtuzumab is a disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS) that has shown efficacy in reducing the annualized relapse rate (ARR), the risk of sustained disability accumulation, and reduction in gadolinium-enhancing T1 lesions in cerebral magnetic resonance imaging (MRI) in patients with EDSS ≤ 5.
Objectives: To study effectiveness outcomes in patients with RRMS with EDSS scores of ≤ 5 or >5.
Methods: Retrospective observational study in patients with highly active RRMS treated with alemtuzumab from March 2015 to March 2017 at Virgen Macarena Hospital, Seville, Spain. Demographic/disease characteristics, ARR, changes in disability, and cerebral MRI findings were collected at enrolment.
Results: EDSS ≤ 5: 35 patients (23 females), mean age: 36.5 years, mean time to diagnosis 13.2 years. 16 patients have received two cycles of treatment. Mean EDSS score decreased from 3.4 to 2.6 (p< 0.05). 22 (62.9%) patients showed a reduction in EDSS, the remaining patients showed no changes in EDSS. ARR decreased from 1.8 to 0.1 (p< 0.05). Two patients (5.7%) experienced relapses after two cycles of treatment. T2 lesions on MRI showed no changes, but the mean number of gadolium enhancing lesions per patient decreased from 2.7 to 0.2 post-treatment (p< 0.05).
EDSS > 5: 27 patients (18 females), mean age: 42.7 years, mean time to diagnosis: 14.6 years. 14 patients have received two cycles of treatment. Mean EDSS score decreased from 6.6 to 5.9 (p< 0.05). 11 (40.7%) patients showed a reduction in EDSS. One patient showed an increase in EDSS of 0.5 points despite receiving the second cycle of treatment. The mean number of T2 lesions on MRI increased from 38.9 to 42.4, and the mean number of gadolinium enhancing lesions decreased from 1.2 to 0.25 (p< 0.05).
Conclusions: Our data show that alemtuzumab is an effective therapy for the treatment of RRMS irrespective of the EDSS score status, with significant improvement in EDSS score, ARR, and gadolinium-enhancing lesions in patients with EDSS score ≤ 5 or > 5. Larger studies are needed to confirm these results given the relatively small size of our patient population.
Disclosure:
Rocío López Ruiz received honoraria as consultant on scientific advisory boards from Biogen, Novartis and Genzyme.
Sara Eichau received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
JL Ruiz-Peña received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
G. Navarro received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.
G. Izquierdo received honoraria as consultant on scientific advisory boards from Biogen, Bayer-Schering, Merck-Serono, Teva and Novartis; has participated in clinical trials/other research projects by Biogen, GSK, Teva and Novartis.